-
Salix to fight FDA after rejection of colitis drug
Salix Pharmaceuticals said Monday that it would fight a U.S. Food and Drug Administration rejection of its proposed ulcerative colitis drug for patients 18 and over.
-
Yahoo, LinkedIn execs join personal genomics startup 23andMe
Company has been getting plenty of attention for its “retail DNA test”, including being named Time Magazine’s invention of the year.
-
Duke begins hiring for launch of health study at N.C. Research Campus
Crystal Overcash says she's proof that you don't need a college degree to work at the N.C. Research Campus.
-
Novartis pays $20M to Triangle firm for potential herpes vaccince
Swiss pharmaceutical giant Novartis AG said Monday it has licensed a potential vaccine for a type of herpes virus from AlphaVax.
-
Novartis pays $20M to Triangle firm for potential herpes vaccince
Swiss pharmaceutical giant Novartis AG said Monday it has licensed a potential vaccine for a type of herpes virus from AlphaVax.
-
U.S. subsidiary of Italian agricultural chemical firm moving HQ to Triangle from Georgia
Sipcam Agro USA, an $80 million company, and two of its subsidiaries are relocating their headquarters to Research Triangle Park, N.C., in January.
-
Startup Parion Sciences receives biodefense grant topping $850,000
Drug development firm to focus on development of potential treatment for people who inhale radioactive materials.
-
Five drug startup firms in Triangle land $1.3M in Biotech Center loans
The Biotech Center also will help the startups with professional services such as business-plan advice.
-
FDA advisers offer support for GSK asthma drug, not a second
Government health advisers have called for restrictions on some long-acting asthma drugs, but spared Advair, a top-selling medication used by millions of patients.
-
Five N.C. firms add 'fellows' through Biotech Center program
Five North Carolina companies are each gaining a research scientist – at no cost – as part of the new “Industrial Fellowships Program” funded by the North Carolina Biotechnology Center.
-
Salix pays $4.5M for rights to potential diarrhea drug
Raleigh-based pharmaceutical firm also agrees to invest $500,000 in Napo Pharmaceuticals, which is developing new compound.
-
Drug firm Patheon, a subject of takeover bid, opens office and lab in RTP
Patheon, a Canadian-based drug development and manufacturing firm, formally opened its newest facilities Wednesday at a headquarters and a lab facility in the Triangle.
-
Former GSK exec quickly making mark as CEO at Sanofi-Aventis
Chris Viehbacher names a new chief financial officer, begins organizational changes at world’s No. 3 drug maker. He took over the company on Dec. 1.
-
Study: More nanotechnology research is needed
The government needs a more comprehensive plan for studying the risks of nanotechnology, the National Research Council said Wednesday.
-
Opposition scuttled biolab sites in N.C., Ga., Homeland Security says
In final memo spelling out why Kansas won, opponents in North Carolina and Georgia are cited as a crucial factor for those states not landing $450M project.
-
NCSU researcher links 'silent epidemic' to tick-born bacteria
UniversityTech: bacteria may be responsible for some chronic and debilitating neurological illnesses in humans, particularly among people with substantial animal contact or arthropod exposure.
-
Durham-based Parion receives $5M from Gilead Sciences
Launch of Phase I clinical trial for drug to treat pulmonary disease triggers payment. Parion recently signed deal worth up to $25M for another drug candidate.
-
North Carolina apparently loses in bid for $450M federal biolab
However, consortium of backers for site near Butner aren’t conceding defeat. Department of Homeland Security reportedly has picked Kansas to house the lab that will focus on biological and agricultural research.
-
North Carolina apparently loses in bid for $450M federal biolab
However, consortium of backers for site near Butner aren’t conceding defeat. Department of Homeland Security reportedly has picked Kansas to house the lab that will focus on biological and agricultural research.
-
North Carolina apparently loses in bid for $450M biodefense lab
The federal government has recommended a site in Kansas for a new $450 million laboratory to study biological threats like anthrax and foot-and-mouth disease, congressional lawmakers and staff said Wednesday.
-
UNC-CH scientists teach enzyme to make synthetic anticoagulant heparin in more varieties
UniversityTech: A synthetic version that can be produced in controlled conditions is key to preventing a recurrence of heparin tragedy linked to China, UNC scientist says.
-
AgBiotech task force aims for convergence of N.C. biotech, farm sectors
'Growing North Carolina's AgBiotech Landscape' is good idea, NCSU economist says. But he warns that state faces growing competition and a tough funding environment. Project co-chair says N.C. could benefit in numerous ways.
-
Biotech-chemical supply services firm in Durham names new CEO
Doe & Ingalls, a provider of raw materials and other supplies for biotechnology, microelectronics and chemical firms, has a new chief executive officer.
-
Tracking the 'wiggles': NCSU scientists present 'moving' theory behind bacterial decision-making
UniversityTech: For first time, NCSU researchers show specific movements of 'transition-state regulators' involved in DNA binding. Discovery could lead to development of new means for combating bacteria.
-
Need headache relief? Try acupuncture, Duke researchers say
Survey of more than 30 studies show the ancient treatment is often more effective than medication.
-
Hunt-led group to develop plan for growing state’s agriculture, biotech sectors
Group of 34 to spearhead formulation of plan for presentation to N.C. General Assembly next spring.
-
Quintiles Transnational acquires molecular diagnostics firm
Deal for Illinois-based company boosts contract research organization’s capabilities for oncology drug research.
-
$250,000 Duke Energy grant to help power N.C. Research Campus lab
Rowan-Cabarrus Community College plans 60,000-square-foot bioprocessing facility.
-
Emory researchers discover strategy for predicting the immunity of vaccines
UniversityTech: Study reveals how a highly successful vaccine triggers robust immune responses.
-
Genomic ‘signature’ could help individualize colon cancer treatment
UniversityTech: Duke researchers develop model that predicts risks of cancer recurrence as well as a patient’s sensitivity to treatments.
-
Diabetes, complications cost patients $4,100 a year, RTI says
In what it says is first study of diabetes-related costs, RTI International says costs increase $158 more each year after initial diagnosis.
-
SARS breakthrough? UNC-CH team helps recreate variant of deadly virus
Project could lead to breakthrough in development for SARS vaccine, treatment says UNC’s Ralph Baric. Baric, an NCSU graduate, leads a Gillings Innovator Lab at Chapel Hill.
-
N.C. biotech firms pressure governor-elect Perdue for cash
North Carolina's biotechnology firms pressed Gov.-elect Beverly Perdue on Monday to commit millions of taxpayer dollars to buoy cash-starved companies that face the prospect of bankruptcy without financing.
-
Argos Therapeutics wraps up remainder of $35.2M in financing
Additional funding is based on progress made in clinical trials, company says. Aurora and Intersouth are among Argos’ backers.
-
Despite rumors, Novartis affirms commitment to Holly Springs plant
The pharmaceutical giant and town officials discussed – and dismissed – a rumor that plant construction would stop. The facility is set to open in 2009 and to employ as many as 450 people.
-
$1.2B in investments help N.C. life sciences industry top 53,000 jobs, report finds
Battelle study says N.C. led U.S. in biotech sector job growth from 2001-2006. Currently, state has 53,200 life science jobs paying average wage of $69,275.
-
Neighbors Quintiles, SAS team up for new training program
Triangle-based firms are developing certification program geared to pharmaceutical industry for study of clinical research trial data.
-
Drug giant Wyeth cuts 10% of Sanford plant work force
The facility makes vaccines. The company had warned earlier this summer that layoffs were likely. It says the plant is important, but it won't rule out future reductions.
-
Innovation, science are keys to economic recovery, UNC-CH chancellor says
In his first visit to N.C. Research Campus in Kannapolis, Holden Thorp praises state's new center for biotech research, discovery.
-
N.C. Research Campus study to research causes, treatments for obesity
Duke University makes weight a major factor in study funded by billionaire David Murdock.
-
At N.C. Research Campus, blending good health and tasty food
Science, cooking and football came together Thursday night at the N.C. Research Campus in a culinary demonstration that was informative and entertaining – not to mention delicious.
-
N.C. Research Campus’ Core Lab tests cooperation early – with 13 interim directors
Scientists from rival universities will put billionaire David Murdock's vision of collaboration to the test as they open the Core Laboratory at the N.C. Research Campus.
-
Thumb exercise? Texting could help prevent obesity through self-monitoring, UNC study says
'Cell phone text messaging is something that’s very familiar to most children now, since they’ve grown up with it,' researcher says. 'By using this technology, we were hoping to make self-monitoring seem more like fun to them and less like work.'
-
$4 million charge helps drive up losses at etrials
Losses increased in the third quarter at eTrials Worldwide even as a new interim chief executive officer strove to rein in costs at the provider of so-called “eClinical” trial services.
-
India-based life-sciences firm launches operations in U.S. with RTP office
Advinus Therapeutics{{/a}} is launching operations in the U.S., with an office in RTP that a former Tranzyme Pharma executive has been hired to manage.
-
Report: GSK to be world's largest pharmaceutical firm by 2012
A British research firm predicts GSK will surpass Pfizer for the top spot, while Roche will be second, Pfizer third.
-
GSK withdraws new drug application for restless legs syndrome treatment
GlaxoSmithKline and development partner XenoPort have withdrawn their new-drug application for a treatment to combat restless legs syndrome.
-
Colorectal cancer treatment costs vary widely, Duke researchers find
New treatments push up costs by nearly $37,000, study shows. Those differences raise questions about ‘what kind of care patients are receiving and whether this economic burden is matched by significant clinical advancements,’ says lead scientist.
-
Duke researchers target lipid molecules associated with heart disease, other ailments
National Institutes of Health to help fund five-year effort to create lipid catalog and to discover new ones.
-
GlaxoSmithKline designates RTP as its sole U.S. headquarters
Decision could mean good news in future for Triangle. GSK has operated dual HQs in RTP and Philadelphia. Drug giant is also trimming 1,000 sales jobs.
-
Researchers in Murdock-funded study find potential markers for hepatitis C treatment
UniversityTech: Duke Clinical Research Institute researchers discover proteins that could help identify who will benefit from standard treatment. Findings are first from grant given to Duke by billionaire David Murdock.
-
Salix wins FDA approval to sell ulcerative colitis drug
Salix Therapeutics has received Food and Drug Administration permission to begin marketing an ulcerative colitis drug called Apriso.
-
Cornerstone BioPharma completes merger, takes new name
Cornerstone BioPharma has a new name – Cornerstone Therapeutics – following the completion of its merger with Critical Therapeutics.
-
Beefing up hepatitis efforts, GSK to acquire California firm for $57M
GlaxoSmithKline will acquire California-based Genelabs Technologies in a deal worth $57 million.
-
Duke uses rare procedure to battle bone cancer
Rashale Arana, of Silkgrass, Belize, is in Charlotte receiving chemotherapy and physical therapy. The Kiwanis Club of Charlotte is paying for her expenses.
-
Durham drug startup lands deal potentially worth $25 million
Parion Sciences receives backing from South Korean firm for potential dry mouth treatment.
-
Venture Capitalist Arthur Pappas to lead Biotechnology Center board
Pappas is founder and managing director of life science-focused VC firm Pappas Ventures. He replaces Sue Cole.
-
Cholesterol drugs may also reduce prostate cancer-related biomarkers, Duke study finds
UniversityTech: Whether the drugs called statins prevent prostate cancer growth or just mask it is not known yet, researchers caution.
-
Breast cancer can strike men – and their children
Each year, thousands of men are diagnosed with a disease most people think affects only women – breast cancer. And they can also pass it down to their children.
-
Cary firm, Auburn to explore nano technology as means to fight cancer
Calvert Research, university researchers to explore using nanobiotechnology drug delivery.
-
Microparticle therapy? Drug-embedded tiny particles could bolster heart function
UniversityTech: Emory, Georgia Tech say research demonstrates effectiveness in animal studies.
-
Watching a brain learn – Duke researchers gain insight to its circuits
UniversityTech: ‘We have been able to visualize the self-organizing process by which the brain uses experience to guide the construction of circuits that are critical for interpreting moving stimuli,’ scientist says.
-
Dara Biosciences raises $2.25M through stock offering, may raise another $8.5M
Dara Biosciences has raised $2.25 million through a discounted sale of stock to what the company described as “certain investors.”
-
MRI as new, more accurate thermometer? Yes, say Duke scientists
UniversityTech: In NIH-funded project, Duke chemists develop means of measuring temperature with magnetic resonance imaging scanners. Technique could lead to improved use of hyperthermia against cancer.
-
Can North Carolina Research Campus stay healthy sickening economic times?
Biotechnology and life science research facility opens Monday in uncertain business climate.
-
$1.5B N.C. Research Campus opens its doors Monday
Billionaire David Murdock’s three-year-old dream of building a life science complex becomes reality as Core Lab, two other buildings formally go into operation with an open house.
-
UNC scientist awarded $2.9M grant to study causes of pediatric cancer
Andrew Olshan, Ph.D., professor and chair of the epidemiology department in the Gillings School of Global Public Health, received the funding from the National Cancer Institute to study neuroblastoma.
-
N.C. Biofuels Center seeks president, two other executives
The N.C. General Assembly-backed initiative distributed job descriptions for the positions, including director of business development and a director for forestry and farming.
-
Using technology from former N.C. firm, Pioneer Surgical launches bone-graft substitute
Tissue regeneration work done by Encelle is part of new nanotechnology-based bone 'scaffold.' Intersouth was an Encelle backer.
-
Scientists find first immune responses to HIV infection are ineffective
UniversityTech: Federally funded study’s results could prove helpful in creating an effective vaccine.
-
Inspire Pharmaceuticals launches clinical trial for glaucoma treatment
Inspire Pharmaceuticals has launched a Phase I clinical trial of a potential new drug to combat glaucoma.
-
FDA decision means delay in $25M payment to PPD
Pharmaceutical Product Development (Nasdaq: PPDI) won’t receive a $25 million milestone payment this year due to a U.S. Food and Drug Administration delay in reviewing a potential diabetes drug.
-
Charlotte Biotechnology Conference to feature N.C. Research Campus
It hasn't officially opened yet, but the N.C. Research Campus is being billed by the Charlotte Biotechnology Conference as the "epicenter" of biotech research, commercialization and collaboration in the Charlotte region.
-
UNC Chapel Hill, Emory receive CDC funding to launch public health preparedness centers
Seven centers will focus on emergency response capabilities.
-
Duke scientists pursue potential blood test for cardiovascular disease
Partnering with California firm, researchers indentify 14 genes connected with deadly killer. Test could not only identify presence of disease but also severity.
-
Novozymes lands $12.3M Department of Energy biofuels contract
Company to match federal commitment in research to improve enzymes that are used for cellulosic ethanol production.
-
Juvenile Diabetes Association picks PPD for clinical services
Pharmaceutical Product Development has been a longtime supporter of diabetes group.
-
Wake Forest takes ‘lab-on-bead’ approach for drug discovery with Biotech Center backing
Nanotechnology could lead to faster chemical screening process. N.C. Biotech Center is providing funding to help project.
-
NCSU takes crabbing to a new locale – farmers’ ponds
UniversityTech: Researchers turning freshwater ponds into blue crab farms.
-
N.C. Biotech Center offers more grant information for researchers
Entrepreneurs and scientists seeking funding support for biotechnology-related projects can access information about grants through an addition to the North Carolina Biotechnology Center’s Web site.
-
Golden Pine licenses technology to launch fourth drug startup company
Drug discovery firm Catena Pharmaceuticals to focus on potential anti-cancer compounds. Its technology is licensed from University of Virginia.
-
N.C. BioNetwork to fund National Center for Biotechnology Workforce
Community College biotech worker training program will provide $200,000 in support to keep Forsyth Tech-based center going. It had lost federal funding.
-
RTP startup lands $750,000 NIH grant for personalized medicine tools
BioMedomics is developing testing platforms based on biomarkers for use at patient points of care.
-
Entegrion wins Navy contract for dried plasma storage, mixing prototype
RTP startup, which is developing variety of blood-related technologies, hopes to begin test of dried plasma product next year.
-
ZenBio lands $1.38M grant for diabetes, obesity project
RTP firm wins SBIR grant to commercialize potential cell-based treatment.
-
GlaxoSmithKline to slice another 850 research and development positions
Some workers in RTP will be affected. GSK employs some 15,000 people internationally who work on drug and product development.
-
Wyeth warns it may cut jobs at Sanford plant this fall
Some 1,200 people work at massive 325,000 square foot vaccine manufacturing facility. Company spokesperson says no final decision has been made about cuts.
-
Biotech center awards research grants topping $700,000
Wake Forest, East Carolina, A&T, UNC-Wilmington researchers receive grants up to $75,000.
-
Open house, dedication set for N.C. Research Campus
Public tours will be offered at the main research building when the North Carolina Research Campus In Kannapolis formally opens its doors on Oct. 20.
-
RTI wins $7.2M contract to evaluate flu treatments
Project to explore use of prescription drugs as part of plan to combat a pandemic.
-
N.C. Research Campus prepares to open doors
‘Three of the latest scientific wonders of the world’ to be unveiled at $1B research hub in Kannapolis on Oct. 20.
-
N.C. Research Campus update: Duke NCRC researchers studying Hepatitis C treatment
Researchers for Duke University's MURDOCK Study want to understand why 50 percent of people treated for hepatitis C never get better.
-
Oriel Therapeutics replaces founder with new CEO
Former Glaxo executive takes over RTP-based firm that closed on $26.5M in venture capital last November. Oriel is developing means of delivering drugs through inhalers.
-
Four life-science startups receive $347,000 in Biotech Center loans
Two RTP, two Charlotte firms land funds for disease-fighting efforts.
-
At N.C. Research Campus, seeing is believing
Tour of biotech research project opens eyes of some visitors.
-
UNC-CH genetics researcher gets $800,000 NIH grant
Brian Strahl, an associate professor of biochemistry and biophysics, received an $800,000 grant covering the next four years. Strahl is researching the so-called “histone code.”
-
Diabetes breakthrough? UNC-CH researchers hail cell transformation discovery
UniversityTech: Scientists turn human skin cells into insulin-producing cells.
-
Talecris receives FDA approval for neurological disorder treatment
Under ‘orphan drug’ status, RTP-based firm receives seven years of market exclusivity for first treatment of disorder known as CIDP.
-
India’s approach to healthcare could boost U.S. hospitals, Duke team says
Faculty group from schools for business, law, medicine conclude that market competition lead to cost, service innovations.
-
GSK forms new team to focus on oncology research
Researchers, clinicians will form ‘bench-to-bed’ unit, says drug giant exec.
-
Addrenex reports proposed drug counters attention-deficit hyperactivity disorder
In Phase III clinical trial, Clonicel reduces 18 ADHD symptoms, Durham drug startup says. Addrenex is developing drug in partnership with Sciele Pharma.
